Targeting SARS-CoV-2 Nonstructural Protein 15 Endoribonuclease: an in silico Perspective

References

• Wu F , ZhaoS, YuBet al. A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269 (2020).
   PubMed Web of Science ®Google Scholar
• Hui DS , IAE, MadaniTAet al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Inf. Dis., 91, 264–266 (2020).
   PubMed Web of Science ®Google Scholar
• Cherry G , RockeJ, ChuMet al. Loss of smell and taste: a new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends. Expert Rev. Anti. Infect. Ther., 18(11), 1165–1170 (2020).
   PubMed Web of Science ®Google Scholar
• Lu R , ZhaoX, LiJet al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395(10224), 565–574 (2020).
   PubMed Web of Science ®Google Scholar
• Xu X , ChenP, WangJet al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci., 63(3), 457–460 (2020).
   PubMed Web of Science ®Google Scholar
• Cui J , LiF, ShiZL. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 17(3), 181–192 (2019).
   PubMed Web of Science ®Google Scholar
• Ortega JT , SerranoML, PujolFH, RangelHR. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target. EXCLI J., 19, 400–409 (2020).
   PubMed Web of Science ®Google Scholar
• Baez-Santos YM , StJohn SE, MesecarAD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res., 115, 21–38 (2015).
   PubMed Web of Science ®Google Scholar
• Liu X , FangP, FangLet al. Porcine deltacoronavirus nsp15 antagonizes interferon-beta production independently of its endoribonuclease activity. Mol. Immunol., 114, 100–107 (2019).
   PubMed Web of Science ®Google Scholar
• Kim Y , JedrzejczakR, MaltsevaNIet al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci., 29(7), 1596–1605 (2020).
   PubMed Web of Science ®Google Scholar
• Bhardwaj K , LiuP, LeibowitzJL, KaoCC. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J. Virol., 86(8), 4294–4304 (2012).
   PubMed Web of Science ®Google Scholar
• Bhardwaj K , SunJ, HolzenburgA, GuarinoLA, KaoCC. RNA recognition and cleavage by the SARS coronavirus endoribonuclease. J. Mol. Biol., 361(2), 243–256 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma J , KumarBhardwaj V, SinghR, RajendranV, PurohitR, KumarS. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2. Food Chem., 346, 128933 (2021).
   PubMed Web of Science ®Google Scholar
• Chikhale RV , SinhaSK, PatilRBet al. In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19. J. Biomol. Struct. Dyn. doi:10.1080/07391102.2020.17842891–15 (2020) ( Epub ahead of print).
   PubMedGoogle Scholar
• Sinha SK , PrasadSK, IslamMAet al. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J. Biomol. Struct. Dyn. doi:10.1080/07391102.2020.17791321–15 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Chandra A , GurjarV, QamarI, SinghN. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. J. Biomol. Struct. Dyn. doi:10.1080/07391102.2020.17751271–11 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Rosenheck RA , LeslieDL, SindelarJet al. Cost–effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry, 163(12), 2080–2089 (2006).
   PubMed Web of Science ®Google Scholar
• Glue P . Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis., 19(Suppl 1), 17–24 (1999).
   PubMedGoogle Scholar
• Elfiky AA , AzzamEB, ShafaaMW. The anti-HCV, sofosbuvir, versus the anti-EBOV remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. Mol. Divers doi:10.1007/s11030-020-10178-z (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Elfiky AA . Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci., 253, 117592 (2020).
   PubMed Web of Science ®Google Scholar
• Elfiky AA , AzzamEB. Novel guanosine derivatives against MERS CoV polymerase: an in silico perspective. J. Biomol. Struct. Dyn., 39(8), 2923–2931 (2021).
   PubMed Web of Science ®Google Scholar
• Mulangu S , DoddLE, DaveyRTJret al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med., 381(24), 2293–2303 (2019).
   PubMed Web of Science ®Google Scholar
• Sheahan TP , SimsAC, GrahamRLet al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med., 9(396), eaal3653 (2017).
   PubMed Web of Science ®Google Scholar
• Yang F , LeiQ, LiLet al. Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity. PLoS ONE, 12(11), e0188025 (2017).
   PubMed Web of Science ®Google Scholar
• Fung HB , KirschenbaumHL, HameedR. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin. Ther., 22(5), 549–572 (2000).
   PubMed Web of Science ®Google Scholar
• Chandwani A , ShuterJ. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther. Clin. Risk Manag., 4(5), 1023–1033 (2008).
   PubMedGoogle Scholar
• Fukuda A , NagaoT, KitaichiT, KogaI, KobayashiA, MiuraT. Safety analysis of Lexiva tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan. Curr. Med. Res. Opin., 36(3), 455–464 (2020).
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T , ScottLJ. Atazanavir: a review of its use in the management of HIV infection. Drugs, 65(16), 2309–2336 (2005).
   PubMed Web of Science ®Google Scholar
• Doyon L , TremblayS, BourgonL, WardropE, CordingleyMG. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res., 68(1), 27–35 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu R , LiY, ZhangXet al. Vapreotide-mediated hierarchical mineralized Ag/Au nanoshells for photothermal anti-tumor therapy. Nanotechnology, 30(5), 055602 (2019).
   PubMed Web of Science ®Google Scholar
• Takahashi H , Ishida-YamamotoA, IizukaH. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin. Exp. Dermatol., 29(5), 526–532 (2004).
   PubMed Web of Science ®Google Scholar
• Cao B , WangY, WenDet al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 382(19), 1787–1799 (2020).
   PubMed Web of Science ®Google Scholar
• Du YX , ChenXP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther., 108(2), 242–247 (2020).
   PubMed Web of Science ®Google Scholar
• Warren TK , WellsJ, PanchalRGet al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 508(7496), 402–405 (2014).
   PubMed Web of Science ®Google Scholar
• Elfiky AA . Novel guanosine derivatives against Zika virus polymerase in silico. J. Med. Virol., 92(1), 11–16 (2020).
   PubMed Web of Science ®Google Scholar
• Elfiky AA . The antiviral sofosbuvir against mucormycosis: an in silico perspective. Future Virol., 14(11), 739–744 (2019).
   Web of Science ®Google Scholar
• Elfiky AA , IbrahimIM. Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico. J. Infect., 82(5), 186–230 (2021).
   PubMed Web of Science ®Google Scholar
• Elfiky AA , IsmailA. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sci., 238, 116958 (2019).
   PubMed Web of Science ®Google Scholar
• Singh R , BhardwajVK, SharmaJ, DasP, PurohitR. Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants. Genomics, 113(1 Pt 2), 707–715 (2021).
   PubMed Web of Science ®Google Scholar
• Bhardwaj VK , SinghR, SharmaJ, RajendranV, PurohitR, KumarS. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. doi:10.1080/07391102.2020.17665721–10 (2020) ( Epub ahead of print).
   Google Scholar
• Elfiky AA . Reply to a letter to the editor. Life Sci., 252, 117715 (2020).
   PubMedGoogle Scholar
• Bhardwaj VK , SinghR, DasP, PurohitR. Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs. Comput. Biol. Med., 128, 104117 (2021).
   PubMed Web of Science ®Google Scholar
• Kim S , ThiessenPA, BoltonEEet al. PubChem substance and compound databases. Nucleic Acids Res., 44(D1), D1202–1213 (2016).
   PubMed Web of Science ®Google Scholar
• Halgren TA . Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem., 17(5–6), 490–519 (1996).
   Web of Science ®Google Scholar
• Halgren TA . Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem., 17(5–6), 520–552 (1996).
   Web of Science ®Google Scholar
• Berman H , HenrickK, NakamuraH. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol., 10(12), 980 (2003).
   PubMedGoogle Scholar
• Studio D . Discovery Studio. Accelrys [2.1] (2008).
   Google Scholar
• Guex N , PeitschMC. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis, 18(15), 2714–2723 (1997).
   PubMed Web of Science ®Google Scholar
• Scott WRP , HünenbergerPH, TironiIGet al. The GROMOS biomolecular simulation program package. J. Phys. Chem. A, 103(19), 3596–3607 (1999).
   Web of Science ®Google Scholar
• Chandra A , GurjarV, QamarI, SinghN. Identification of potential inhibitors of SARS-CoV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. J. Biomol. Struct. Dyn. doi:10.1080/07391102.2020.17751271–11 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Trott O , OlsonAJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31(2), 455–461 (2010).
   PubMed Web of Science ®Google Scholar
• Morris GM , HueyR, LindstromWet al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem., 30(16), 2785–2791 (2009).
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System, Version 2.4.1 Schrödinger, LLC.
   Google Scholar
• Elfiky AA . Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci., 248, 117477 (2020).
   PubMed Web of Science ®Google Scholar
• Jokhakar PH , KalariaR, PatelHK. In silico docking studies of antimalarial drug hydroxychloroquine to SARS-CoV proteins: an emerging pandemic worldwide. ChemRxiv.https://doi.org/doi:10.26434/chemrxiv 12488804 v1 (2020) ( Epub ahead of print).
   Google Scholar
• Turnbull AP , BoydSM. Targeting cancer using fragment based drug discovery. Anticancer Agents Med. Chem., 12(1), 40–48 (2012).
   PubMed Web of Science ®Google Scholar
• Meng XY , ZhangHX, MezeiM, CuiM. Molecular docking: a powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des., 7(2), 146–157 (2011).
   PubMed Web of Science ®Google Scholar
• Egli M , TereshkoV, MushudovGN, SanishviliR, LiuX, LewisFD. Face-to-face and edge-to-face pi-pi interactions in a synthetic DNA hairpin with a stilbenediether linker. J. Am. Chem. Soc., 125(36), 10842–10849 (2003).
   PubMed Web of Science ®Google Scholar
• Uddin N , AhmedS, KhanAM, MazharolHoque M, HalimMA. Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy. J. Biomol. Struct. Dyn., 38(3), 901–917 (2020).
   PubMed Web of Science ®Google Scholar
• Costa PJ . The halogen bond: nature and applications. Phys. Sci. Rev., 2(11), 1–16 (2017).
   Google Scholar
• Pedersen SW , HultqvistG, StromgaardK, JemthP. The role of backbone hydrogen bonds in the transition state for protein folding of a PDZ domain. PLoS ONE, 9(4), e95619 (2014).
   PubMed Web of Science ®Google Scholar
• Van De Waterbeemd H , GiffordE. ADMET in silico modelling: towards prediction paradise?Nat. Rev. Drug Discov., 2(3), 192–204 (2003).
   PubMed Web of Science ®Google Scholar
• Bello M , Martinez-MunozA, Balbuena-RebolledoI. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. J. Mol. Model, 26(12), 340 (2020).
   PubMed Web of Science ®Google Scholar
• Genheden S , RydeU. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov., 10(5), 449–461 (2015).
   PubMed Web of Science ®Google Scholar